BioStock Investor Pitch: Biosergen

In the BioStock Studio, Swedish Biosergen talks about the company’s vision, market plan and strategy to take its product through the first patient study and on towards a global market. Strengthened by its recent agreement with Alkem, the company intends to advance its antifungal drug candidate BSG005 further by an ongoing rights issue of SEK 40.5 million.

Watch Biosergens CEO Tine Kold Olesen present the company in the BioStock Investor Pitch:

BioStock Investor Pitch – Biosergen

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/